2020 ESC Digital Experience congress – what is new? Meeting Proceedings
Article Sidebar
Published:
Sep 30, 2020
Keywords:
hypertension, guidelines, atrial fibrillation, cardiovascular risk, COVID-19, SGLT2 inhibitors
Main Article Content
Abstract
The 2020 ESC Digital Experience congress gathered 125 thousand participants from 211 countries. Four new guidelines were released including diagnosis and management of atrial fibrillation, management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, sports cardiology and exercise in patients with cardiovascular disease, and management of adult congenital heart disease. Several landmark clinical trials were presented including studies assessing: the effects of SGLT2 inhibitors (DAPA-CKD and EMPEROR-Reduced trials), potential benefits of colchicine (LoDoCo2 trial) and safety of drugs blocking renin–angiotensin in COVID-19 patients (BRACE CORONA trial). New meta-analyses confirmed benefits of antihypertensive treatment and cancer-related safety of cardiovascular drugs. This short review summarizes the most important results presented during the congress and discusses their clinical implications.
Article Details
How to Cite
Narkiewicz, K. (2020). 2020 ESC Digital Experience congress – what is new?. Medycyna Faktow (J EBM), 13(3(48), 370-374. https://doi.org/10.24292/01.MF.0320.12
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020. http://doi.org/10.1093/eurheartj/ehaa612.
2. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020. http://doi.org/10.1093/eurheartj/ehaa575.
3. The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC). 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2020. http://doi.org/10.1093/eurheartj/ehaa605.
4. The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020. http://doi.org/10.1093/eurheartj/ehaa554.
5. Heerspink HJL, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2024816.
6. Packer M, Anker SD, Butler J et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2022190.
7. Zannad F, Ferreira JP, Pocock SJ et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020; 396(10254): 819-29. http://doi.org/10.1016/S0140-6736(20)31824-9.
8. Tardif JC, Kouz S, Waters DD et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381: 2497-505.
9. Nidorf SM, Fiolet ATL, Mosterd A et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2021372.
10. Mancia G, Rea F, Ludergnani M et al. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; 382: 2431-40.
11. Lopes RD, Macedo AVS, de Barros e Silva PGM et al. Continuing versus suspending angiotensyn converting enzyme inhibitors and angiotensyn receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – The BRACE CORONA Trial. Am Heart J. 2020; 226: 49-59.
12. Rahimi K, Canoy D, Nazarzadeh M et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC). BMJ Open. 2019; 9(5): e028698.
13. Unger T, Borghi C, Charchar F et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75: 1334-57.
14. Warchol-Celinska E, Prejbisz A, Dobrowolski P et al. Systematic and Multidisciplinary Evaluation of Fibromuscular Dysplasia Patients Reveals High Prevalence of Previously Undetected Fibromuscular Dysplasia Lesions and Affects Clinical Decisions: The ARCADIA-POL Study. Hypertension. 2020; 75: 1102-9.
15. Grassi G, Quarti-Trevano F, Seravalle G et al. Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers. Hypertension. 2020; 76: 577-82.
16. Kishi T. Heart rate Is the Clinical Indicator of Sympathetic Activation and Prognostic Value of Cardiovascular Risks in Patients With Hypertension. Hypertension. 2020; 76: 323-4.
17. Tykarski A, Filipiak KF, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5: 1-86.
18. Kuhlkamp V, Schirdewan A, Stangl K et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000; 36: 139-46.
19. van Veldhuisen DJ, Aass H, El Allaf D et al; MERIT-HF Study Group. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail. 2006; 8: 539-46.
2. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020. http://doi.org/10.1093/eurheartj/ehaa575.
3. The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC). 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2020. http://doi.org/10.1093/eurheartj/ehaa605.
4. The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020. http://doi.org/10.1093/eurheartj/ehaa554.
5. Heerspink HJL, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2024816.
6. Packer M, Anker SD, Butler J et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2022190.
7. Zannad F, Ferreira JP, Pocock SJ et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020; 396(10254): 819-29. http://doi.org/10.1016/S0140-6736(20)31824-9.
8. Tardif JC, Kouz S, Waters DD et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381: 2497-505.
9. Nidorf SM, Fiolet ATL, Mosterd A et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2021372.
10. Mancia G, Rea F, Ludergnani M et al. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; 382: 2431-40.
11. Lopes RD, Macedo AVS, de Barros e Silva PGM et al. Continuing versus suspending angiotensyn converting enzyme inhibitors and angiotensyn receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – The BRACE CORONA Trial. Am Heart J. 2020; 226: 49-59.
12. Rahimi K, Canoy D, Nazarzadeh M et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC). BMJ Open. 2019; 9(5): e028698.
13. Unger T, Borghi C, Charchar F et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75: 1334-57.
14. Warchol-Celinska E, Prejbisz A, Dobrowolski P et al. Systematic and Multidisciplinary Evaluation of Fibromuscular Dysplasia Patients Reveals High Prevalence of Previously Undetected Fibromuscular Dysplasia Lesions and Affects Clinical Decisions: The ARCADIA-POL Study. Hypertension. 2020; 75: 1102-9.
15. Grassi G, Quarti-Trevano F, Seravalle G et al. Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers. Hypertension. 2020; 76: 577-82.
16. Kishi T. Heart rate Is the Clinical Indicator of Sympathetic Activation and Prognostic Value of Cardiovascular Risks in Patients With Hypertension. Hypertension. 2020; 76: 323-4.
17. Tykarski A, Filipiak KF, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5: 1-86.
18. Kuhlkamp V, Schirdewan A, Stangl K et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000; 36: 139-46.
19. van Veldhuisen DJ, Aass H, El Allaf D et al; MERIT-HF Study Group. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail. 2006; 8: 539-46.